We are analyzing https://link.springer.com/article/10.1007/s12032-009-9218-8.

Title:
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy | Medical Oncology
Description:
For patients with docetaxel-resistant hormone-refractory prostate cancer (HRPC) no standard chemotherapeutic treatment exists. In this study, we evaluate the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in this patient population. Patients with metastatic HRPC with disease progression under docetaxel-based chemotherapy were eligible. The primary endpoint was prostate-specific antigen (PSA) response. Secondary endpoints were survival and toxicity. Low-dose CP (50 mg/d) and dexamethasone (1 mg/d) were administered orally in a metronomic manner. Treatment was continued until disease progression or intolerable side effects occurred. Seventeen patients were enrolled in this study. The median follow-up was 12 weeks (range: 4–60). Median age was 68 years (range: 42–85). Median PSA at study entry was 134 ng/ml (range: 46.0–6554). Nine patients had a PSA response (median 44.4%), four patients ≥50% and five patients <50%. Eight patients had a PSA progression. Overall survival was 24 months. Five patients reported a decrease in bone pain after 4 weeks
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, article, prostate, cas, pubmed, google, scholar, patients, cyclophosphamide, chemotherapy, metronomic, study, hormonerefractory, treatment, nelius, advanced, docetaxel, metastatic, oral, phase, dose, estramustine, prednisone, clin, privacy, cookies, content, oncology, psa, lowdose, combination, access, therapy, data, publish, research, search, clinical, docetaxelresistant, secondline, thomas, klatte, hrpc, efficacy, response, toxicity, median, trial, oncol, refractory,

Topics {✒️}

otto-von-guericke-university magdeburg experimental drug-resistant cancer hormone-refractory prostate cancer month download article/chapter androgen-independent prostate cancer related subjects androgen-independent prostate carcinoma prospective phase-ii trial low-dose metronomic combined drug-specific effects metronomic cyclophosphamide therapy intermittent bolus-dose cyclophosphamide advanced prostate cancer based metronomic chemotherapy docetaxel-resistant hrpc androgen deprivation therapy docetaxel-based chemotherapy prostate-specific antigen full article pdf clin prostate cancer advanced prostatic cancer phase ii trial metronomic therapy dose continuous chemotherapy target tumor angiogenesis privacy choices/manage cookies metastatic hrpc chemotherapy improves efficacy low-dose cp cancer chemother pharmacol cyclophosphamide administered continuously phase-ii study phase ii study prostate cancer article nelius oral -dose cyclophosphamide tumor growth suppression clinical outcome hormone-naive patients cyclophosphamide versus cyclophosphamide check access instant access line chemotherapy tumor microenvironment contributes low-toxicity profile european economic area anti-tumour effect david geffen school prostate carcinoma convenient oral administration

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
         description:For patients with docetaxel-resistant hormone-refractory prostate cancer (HRPC) no standard chemotherapeutic treatment exists. In this study, we evaluate the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in this patient population. Patients with metastatic HRPC with disease progression under docetaxel-based chemotherapy were eligible. The primary endpoint was prostate-specific antigen (PSA) response. Secondary endpoints were survival and toxicity. Low-dose CP (50 mg/d) and dexamethasone (1 mg/d) were administered orally in a metronomic manner. Treatment was continued until disease progression or intolerable side effects occurred. Seventeen patients were enrolled in this study. The median follow-up was 12 weeks (range: 4–60). Median age was 68 years (range: 42–85). Median PSA at study entry was 134 ng/ml (range: 46.0–6554). Nine patients had a PSA response (median 44.4%), four patients ≥50% and five patients <50%. Eight patients had a PSA progression. Overall survival was 24 months. Five patients reported a decrease in bone pain after 4 weeks' treatment. No grade 3 and 4 toxicities were noted. In this study, low-dose metronomically administered CP demonstrated efficacy as a second-line treatment in patients with docetaxel-resistant HRPC. The treatment was well tolerated and almost without toxicity. Further advantages of low-dose CP were its convenient oral administration, dosing schedule, low cost, and low-toxicity profile. These attributes in combination with immunoregulatory and antiangiogenic potentials make CP also a prime candidate for combination with other treatment regimens.
         datePublished:2009-04-14T00:00:00Z
         dateModified:2009-04-14T00:00:00Z
         pageStart:363
         pageEnd:367
         sameAs:https://doi.org/10.1007/s12032-009-9218-8
         keywords:
            Metronomic chemotherapy
            Cyclophosphamide
            Docetaxel
            Hormone-refractory prostate cancer
            Angiogenesis
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-009-9218-8/MediaObjects/12032_2009_9218_Fig1_HTML.gif
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:27
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Thomas Nelius
               affiliation:
                     name:Texas Tech University Health Sciences Center
                     address:
                        name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                        type:PostalAddress
                     type:Organization
                     name:Otto-von-Guericke-University Magdeburg
                     address:
                        name:Department of Urology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Tobias Klatte
               affiliation:
                     name:David Geffen School of Medicine at UCLA
                     address:
                        name:Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Werner de Riese
               affiliation:
                     name:Texas Tech University Health Sciences Center
                     address:
                        name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Allan Haynes
               affiliation:
                     name:Texas Tech University Health Sciences Center
                     address:
                        name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephanie Filleur
               affiliation:
                     name:Texas Tech University Health Sciences Center
                     address:
                        name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
      description:For patients with docetaxel-resistant hormone-refractory prostate cancer (HRPC) no standard chemotherapeutic treatment exists. In this study, we evaluate the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in this patient population. Patients with metastatic HRPC with disease progression under docetaxel-based chemotherapy were eligible. The primary endpoint was prostate-specific antigen (PSA) response. Secondary endpoints were survival and toxicity. Low-dose CP (50 mg/d) and dexamethasone (1 mg/d) were administered orally in a metronomic manner. Treatment was continued until disease progression or intolerable side effects occurred. Seventeen patients were enrolled in this study. The median follow-up was 12 weeks (range: 4–60). Median age was 68 years (range: 42–85). Median PSA at study entry was 134 ng/ml (range: 46.0–6554). Nine patients had a PSA response (median 44.4%), four patients ≥50% and five patients <50%. Eight patients had a PSA progression. Overall survival was 24 months. Five patients reported a decrease in bone pain after 4 weeks' treatment. No grade 3 and 4 toxicities were noted. In this study, low-dose metronomically administered CP demonstrated efficacy as a second-line treatment in patients with docetaxel-resistant HRPC. The treatment was well tolerated and almost without toxicity. Further advantages of low-dose CP were its convenient oral administration, dosing schedule, low cost, and low-toxicity profile. These attributes in combination with immunoregulatory and antiangiogenic potentials make CP also a prime candidate for combination with other treatment regimens.
      datePublished:2009-04-14T00:00:00Z
      dateModified:2009-04-14T00:00:00Z
      pageStart:363
      pageEnd:367
      sameAs:https://doi.org/10.1007/s12032-009-9218-8
      keywords:
         Metronomic chemotherapy
         Cyclophosphamide
         Docetaxel
         Hormone-refractory prostate cancer
         Angiogenesis
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-009-9218-8/MediaObjects/12032_2009_9218_Fig1_HTML.gif
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:27
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Thomas Nelius
            affiliation:
                  name:Texas Tech University Health Sciences Center
                  address:
                     name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                     type:PostalAddress
                  type:Organization
                  name:Otto-von-Guericke-University Magdeburg
                  address:
                     name:Department of Urology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Tobias Klatte
            affiliation:
                  name:David Geffen School of Medicine at UCLA
                  address:
                     name:Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Werner de Riese
            affiliation:
                  name:Texas Tech University Health Sciences Center
                  address:
                     name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Allan Haynes
            affiliation:
                  name:Texas Tech University Health Sciences Center
                  address:
                     name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephanie Filleur
            affiliation:
                  name:Texas Tech University Health Sciences Center
                  address:
                     name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:27
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Texas Tech University Health Sciences Center
      address:
         name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
         type:PostalAddress
      name:Otto-von-Guericke-University Magdeburg
      address:
         name:Department of Urology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
         type:PostalAddress
      name:David Geffen School of Medicine at UCLA
      address:
         name:Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, USA
         type:PostalAddress
      name:Texas Tech University Health Sciences Center
      address:
         name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
         type:PostalAddress
      name:Texas Tech University Health Sciences Center
      address:
         name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
         type:PostalAddress
      name:Texas Tech University Health Sciences Center
      address:
         name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Thomas Nelius
      affiliation:
            name:Texas Tech University Health Sciences Center
            address:
               name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
               type:PostalAddress
            type:Organization
            name:Otto-von-Guericke-University Magdeburg
            address:
               name:Department of Urology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Tobias Klatte
      affiliation:
            name:David Geffen School of Medicine at UCLA
            address:
               name:Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Werner de Riese
      affiliation:
            name:Texas Tech University Health Sciences Center
            address:
               name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
               type:PostalAddress
            type:Organization
      name:Allan Haynes
      affiliation:
            name:Texas Tech University Health Sciences Center
            address:
               name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
               type:PostalAddress
            type:Organization
      name:Stephanie Filleur
      affiliation:
            name:Texas Tech University Health Sciences Center
            address:
               name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
      name:Department of Urology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
      name:Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, USA
      name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
      name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
      name:Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(125)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

6.37s.

LINK . SPRINGER . COM {}